Cabaletta Bio (CABA) Competitors

Replimune Group (NASDAQ:REPL) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.

Does the media prefer REPL or CABA?

In the previous week, Replimune Group had 17 more articles in the media than Cabaletta Bio. MarketBeat recorded 26 mentions for Replimune Group and 9 mentions for Cabaletta Bio. Replimune Group's average media sentiment score of 0.65 beat Cabaletta Bio's score of 0.62 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	5 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in REPL or CABA?

92.5% of Replimune Group shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 9.9% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more risk & volatility, REPL or CABA?

Replimune Group has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Cabaletta Bio has a beta of 2.42, suggesting that its stock price is 142% more volatile than the S&P 500.

Do analysts prefer REPL or CABA?

Replimune Group presently has a consensus target price of $16.80, indicating a potential upside of 55.56%. Cabaletta Bio has a consensus target price of $27.30, indicating a potential upside of 800.99%. Given Cabaletta Bio's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.17
Cabaletta Bio	0 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in REPL or CABA?

Replimune Group received 75 more outperform votes than Cabaletta Bio when rated by MarketBeat users. However, 72.50% of users gave Cabaletta Bio an outperform vote while only 63.04% of users gave Replimune Group an outperform vote.

Company	Underperform	Outperform
Replimune Group	Outperform Votes 162 63.04%	Underperform Votes 95 36.96%
Cabaletta Bio	Outperform Votes 87 72.50%	Underperform Votes 33 27.50%

Is REPL or CABA more profitable?

Cabaletta Bio's return on equity of -47.53% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-53.12%	-41.49%
Cabaletta Bio	N/A	-47.53%	-43.92%

Which has better valuation and earnings, REPL or CABA?

Replimune Group is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$215.79M	-$3.05	-3.54
Cabaletta Bio	N/A	N/A	-$67.68M	-$2.15	-1.41

Summary

Cabaletta Bio beats Replimune Group on 9 of the 16 factors compared between the two stocks.